FOXO4-DRI Human Trials: Status, Evidence Gaps, and What to Watch (2026) As of July 2026, no human trial of FOXO4-DRI has ever been registered or published
Available from URL: [Accessed 2008 Jul 1] Calabrese V, Ravagna A, Colombrita C, et al
A number of studies have looked at increasing glutathione levels in people with CF to improve lung function.[ref] Related article : Cystic fibrosis: How to check to see if you are a carrier of a CFTR mutation Alcohol: Long-term or heavy alcohol use depletes glutathione levels in the liver, causing alcoholic liver disease
Muscle & peptides
Patients should be reviewed 812 weeks after commencing treatment to assess: Symptomatic improvement, particularly resolution of fatigue and neurological symptoms Haematological response (normalisation of haemoglobin and mean cell volume) Reticulocyte count typically rises within one week, indicating bone marrow response Repeat serum B12 testing is generally not useful after starting parenteral therapy, as levels remain elevated for months